News and Events

For all media enquiries, please contact Breakthrough Media Centre:

Press office
Email: press@breakthrough.org.uk
Tel: 020 7025 2432 / 2460
Fax: 020 7025 2401
Out of hours: 07778 682001

  • Breakthrough Breast Cancer scientists develop new method to predict patient response to Herceptin

    28 Jul 2009
    Breakthrough Breast Cancer scientists have taken a significant step towards personalising cancer treatment by developing a new method to predict a patient’s response to the drug Herceptin. Scientists based in Edinburgh are the first to use computer modelling to predict individual responses to cancer treatment. The results are published in the journal Cancer Research on 28 July 2009.

  • New Drug Targeting Cancer Weakness Shows Great Promise

    24 Jun 2009
    Scientists at The Institute of Cancer Research and The Royal Marsden Hospital, working with pharmaceutical company AstraZeneca, have completed a clinical trial demonstrating the great promise of a completely new type of cancer treatment. The results are announced today in The New England Journal of Medicine.

  • Scientists open the door to future 2-in-1 breast cancer treatments

    11 Jun 2009
    Scientists from the Breakthrough Breast Cancer Research Centre based at the Institute of Cancer Research have shown for the first time that it is possible for one drug to simultaneously attack cancer cells in two completely different ways. Researchers now hope this discovery could lead to further two-in-one treatments – meaning breast cancer patients could potentially need to take fewer drugs to treat tumours in the future.

  • Domainex Collaboration on Novel Drug Targets

    20 Mar 2009
    Domainex today announced a collaboration on new exciting drug discovery programmes with the Breakthrough Breast Cancer Research Centre and The Institute of Cancer Research (ICR) to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon.

  • CDK10 is an Important Determinant of Resistance to EndocrineTherapy

    05 Feb 2008
    Scientists at the Breakthrough Breast Cancer Research Centre have identified how some breast cancers may become resistant to hormone treatments like tamoxifen. The study, published in the February issue of Cancer Cell, shows for the first time that a protein called CDK10 is able to control the development of tamoxifen resistance in hormone sensitive breast cancer, and has potentially important implications in the treatment of women with this form of the disease.

  • Patients begin enrolling in studies to determine if women with BRCA 1 & 2 positive cancer may receive greater benefit from new treatment

    19 Jun 2007
    AstraZeneca Collaborates with Myriad Genetics on Phase 2 Trials. AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 positive breast and ovarian cancer. Myriad Genetics, Inc. (Nasdaq: MYGN, www.myriad.com), is providing the molecular diagnostic testing (BRACAnalysis™) for these trials. Dr Andrew Tutt, clinician scientist at the Breakthrough Breast Cancer Research Centre and breast oncologist at Guy’s Hospital, London is Lead Investigator for the trials.

  • BRCA1 dysfunction in sporadic basal-like breast cancer

    29 Mar 2007
    Breakthrough scientists have identified a high prevalence of BRCA1 dysfunction in basal-like breast cancers. This finding could be exploited to develop novel targeted therapies for this particular type of breast cancer.